NCT04766814Completed
Epigenetic Analysis of Regulation of the Inflammasome-activating NLRP3 Gene in Monocytes From Atrial Fibrillation Patients and Controls
Source: ClinicalTrials.gov · Last updated 25 Apr 2024
Brief summary (registry, in English)
The study will analyze blood from volunteers to determine whether there is an underlying epigenetic cause of the inflammation of the heart associated with atrial fibrillation (AF) and its progression with age. Confirming the regions of epigenetic elements associated with upregulation of the inflammatory genes will help the investigators in identifying target sites for developing future therapeutic interventions. The investigators propose to confirm the monocyte-cell type specific DNA methylation profile of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) and determine the age-related and AF-related changes in DNA methylation and expression of NLRP3 in monocytes. This study will provide insights into the epigenetic regulation of NLRP3 in young and elderly patients, as well as in AF patients vs. controls which will help in devising methods of modulating NLRP3 expression and decreasing cardiac fibrosis progression.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 29 (actual)
- First submitted
- 8 Feb 2021
- Start date
- Oct 2021
- Primary completion date
- Feb 2024
- Lead sponsor
- Tulane University
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT04766814
What you commit to
- Study type: Observational
- Participants enrolled: 29
- From Oct 2021 to the primary completion date, Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous left atrial ablation or any type of valvular surgery
- Patients who are taking medications like Ibuprofen, Toradol, Naproxen and other common over-the -counter NSAIDs.
Other
- Women who are pregnant
- Terminally ill patients
Who the study is looking for
- Subjects aged 18 or above,
- Control Group scheduled for routine annual health check-up and healthy blood donors without any documentation of cardiovascular disease or other serious immune-related illnesses, such as diabetes, hypertension, autoimmune arthritis etc
- healthy women subjects between the ages of 50-80 years
- healthy women subjects between the ages of 20-30 years.
- Study Patients -women between the ages of 50 - 80 years diagnosed with AF as evidenced by rhythm strips or written documentation.
Age in the registry: 20 years to 80 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tulane University Medical Center Coordinator of this site? Confirm its status | New Orleans | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.